Limits...
Tumor suppressor p53 protein expression: prognostic significance in patients with low-risk myelodysplastic syndrome.

Duarte FB, Gonçalves RP, Barbosa MC, Rocha Filho FD, de Jesus Dos Santos TE, Dos Santos TN, de Vasconcelos PR - Rev Bras Hematol Hemoter (2014)

Bottom Line: However, these patients often show very variable clinical outcomes.At diagnosis, this group of patients also presented clinical features characteristic of a poor prognosis more often than patients who did not express p53.Furthermore, patients expressing p53 had a shorter median survival time compared to those without p53 expression.

View Article: PubMed Central - PubMed

Affiliation: Universidade Federal do Ceará (UFC), Fortaleza, CE, Brazil.

No MeSH data available.


Related in: MedlinePlus

Strong staining (40%) of the p53 protein in bone marrow (streptavidin–biotin – magnification: 400×).
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4109734&req=5

fig0005: Strong staining (40%) of the p53 protein in bone marrow (streptavidin–biotin – magnification: 400×).

Mentions: Table 1 shows the clinical characteristics for patients as well as their status for p53 expression at diagnosis. Of the 38 patients who participated in the study, 13 (34.21%) showed p53 protein expression in the nuclei of hematopoietic cells from their bone marrow (Figure 1). Interestingly, p53 expression appears to be correlated with a higher age at diagnosis (66.88 years), while patients who were diagnosed at a younger age (54.78 years) were less likely to express p53 protein (p-value = 0.0341). The hemoglobin level, hematocrit concentration, and white blood cell count were significantly lower in patients with p53 expression (95.41 g/dL, 29.91%, 3.255 × 109/L, respectively) than in patients without p53 expression (11.17 g/dL, 33.86% and 5.236 × 109/L, respectively) (p-value < 0.05).


Tumor suppressor p53 protein expression: prognostic significance in patients with low-risk myelodysplastic syndrome.

Duarte FB, Gonçalves RP, Barbosa MC, Rocha Filho FD, de Jesus Dos Santos TE, Dos Santos TN, de Vasconcelos PR - Rev Bras Hematol Hemoter (2014)

Strong staining (40%) of the p53 protein in bone marrow (streptavidin–biotin – magnification: 400×).
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4109734&req=5

fig0005: Strong staining (40%) of the p53 protein in bone marrow (streptavidin–biotin – magnification: 400×).
Mentions: Table 1 shows the clinical characteristics for patients as well as their status for p53 expression at diagnosis. Of the 38 patients who participated in the study, 13 (34.21%) showed p53 protein expression in the nuclei of hematopoietic cells from their bone marrow (Figure 1). Interestingly, p53 expression appears to be correlated with a higher age at diagnosis (66.88 years), while patients who were diagnosed at a younger age (54.78 years) were less likely to express p53 protein (p-value = 0.0341). The hemoglobin level, hematocrit concentration, and white blood cell count were significantly lower in patients with p53 expression (95.41 g/dL, 29.91%, 3.255 × 109/L, respectively) than in patients without p53 expression (11.17 g/dL, 33.86% and 5.236 × 109/L, respectively) (p-value < 0.05).

Bottom Line: However, these patients often show very variable clinical outcomes.At diagnosis, this group of patients also presented clinical features characteristic of a poor prognosis more often than patients who did not express p53.Furthermore, patients expressing p53 had a shorter median survival time compared to those without p53 expression.

View Article: PubMed Central - PubMed

Affiliation: Universidade Federal do Ceará (UFC), Fortaleza, CE, Brazil.

No MeSH data available.


Related in: MedlinePlus